1
|
Barth SM, Schreitmüller CM, Proehl F, Oehl K, Lumpp LM, Kowalewski DJ, Di Marco M, Sturm T, Backert L, Schuster H, Stevanović S, Rammensee HG, Planz O. Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy. PLoS One 2016; 11:e0167017. [PMID: 27893789 PMCID: PMC5125661 DOI: 10.1371/journal.pone.0167017] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Accepted: 11/07/2016] [Indexed: 12/11/2022] Open
Abstract
There are limitations in pre-clinical settings using mice as a basis for clinical development in humans. In cancer, similarities exist between humans and dogs; thus, the dog patient can be a link in the transition from laboratory research on mouse models to clinical trials in humans. Knowledge of the peptides presented on MHC molecules is fundamental for the development of highly specific T cell-based immunotherapies. This information is available for human MHC molecules but is absent for the canine MHC. In the present study, we characterized the binding motif of dog leukocyte antigen (DLA) class I allele DLA-88*50101, using human C1R and K562 transfected cells expressing the DLA-88*50101 heavy chain. MHC class I immunoaffinity-purification revealed 3720 DLA-88*50101 derived peptides, which enabled the determination of major anchor positions. The characterized binding motif of DLA-88*50101 was similar to HLA-A*02:01. Peptide binding analyses on HLA-A*02:01 and DLA-88*50101 via flow cytometry showed weak binding of DLA-88*50101 derived peptides to HLA-A*02:01, and vice versa. Our results present for the first time a detailed peptide binding motif of the canine MHC class I allelic product DLA-88*50101. These data support the goal of establishing dogs as a suitable animal model for the evaluation and development of T cell-based cancer immunotherapies, benefiting both dog and human patients.
Collapse
Affiliation(s)
- Sharon M. Barth
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
| | | | - Franziska Proehl
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
| | - Kathrin Oehl
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
- Institute for Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Leonie M. Lumpp
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
| | - Daniel J. Kowalewski
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
- Immatics, Biotechnologies GmbH, Tuebingen, Germany
| | - Moreno Di Marco
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
| | - Theo Sturm
- Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, Zurich, Switzerland
- Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Linus Backert
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
- Applied Bioinformatics, Center of Bioinformatics and Department of Computer Science, University of Tuebingen, Tuebingen, Germany
| | - Heiko Schuster
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
- Institute for Surgical Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Stefan Stevanović
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
| | - Hans-Georg Rammensee
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
| | - Oliver Planz
- Department of Immunology, Institute of Cell Biology, University of Tuebingen, Tuebingen, Germany
- * E-mail:
| |
Collapse
|
2
|
Barth SM. Integrating payer and provider risk through capitation. Manag Care Q 1997; 5:19-24. [PMID: 10164645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Capitation payment mechanisms promote conservative use of medical resources by transferring risk to the decision maker, the physician. However, there is another view of capitation: defining common risk between provider-driven organizations (i.e., physician/hospital organizations (PHOs) or integrated delivery systems (IDS), and risk-managing entities such as HMOs or insurance companies. This article discusses a strategy to align provider and risk manager incentives to share the risks and rewards for a total book of business or population.
Collapse
Affiliation(s)
- S M Barth
- Independence Blue Cross Family of Companies, Philadelphia, PA, USA
| |
Collapse
|